Life Sciences Archive » October, 2013

Life Sciences - October, 2013

282 articles

• J&J Gouged $2M For HIV Meds, Health Care Nonprofit Says
• Ranbaxy Sues Actavis To Block Generic Absorica Acne Drug
• Clinical Trial Deaths Lead Ariad To Halt Iclusig Sales
• J&J Unit Slapped With $4M Verdict Over Topamax Birth Defects
• Risky Business Of FDA Mobile Medical Apps
• AstraZeneca Discloses US Investigation Into Heart Drug Trial
• Biopharma Co. Misled Investors On Cancer Drug Progress: Suit
• FDA Launches Two-Prong Attack On Drug Shortages
• Sequenom Patent For Prenatal DNA Test Invalidated
• Deals Rumor Mill: Oaktree Capital, Barrick, General Atlantic
• Genentech Seeks Trim Of Eli Lilly's Patent Invalidation Suit
• 6th Circ. Won't Hear Appeal Of Darvocet Suit Remand
• Insurer Brings $3M Medpace Coverage Suit To Fed. Court
• Butler Snow Adds Baker Botts Product Liability Expert In NY
• FTC Says Marketer Exaggerated Weight Loss Claims
• Legal Demand Is Up — How Are Law Departments Managing?
• 4 Compliance-Focused Reforms That Would Improve FCA
• FDA Chides Sunovion Over Misstating Brovana Risks, Benefits
• Fed. Circ. Partially Revives AstraZeneca Asthma Drug IP Row
• K-V, Secured Lenders Reach $5M Deal To End Interest Row
• Okla. Supreme Court Gives Harsh Take On Abortion Drug Law
• AEIC Allowed To Seek $4M Fee In Clinical Trial Row
• Allergan Can't Beat Widower's Botox Poisoning Suit
• To Dodge Mensing, Plaintiffs May Target Foreign Drugmakers
• UK To Ban Hospitals' Use Of Many Metal Hip Implants
• Bill Risks Confusion To Curb FDA's Already-Lax App Oversight
• Synthes' Spinal Implant Patent Invalid, Fed. Circ. Affirms
• Takeaways From McPhee V. DePuy's Preemption Pronouncement
• Walgreens Sued Over Cartilage Rebuilding Supplement
• Honigman Miller Adds Patent Pro To IP Practice Group
• Sales Rep Claims Eli Lilly Reneged On Contract Incentives
• Star Scientific Says Shareholder Drug Suit Falls Short
• MedLab Seeks Ch. 11 Amid Medicare Reimbursement Cuts
• Jury Sides With Roche In Age Bias Trial
• FDA Proposes New Animal Food Safety Regs
• Canadian Court Won't Shrink Paxil Birth Defect Class
• Fed. Circ. Curbs Future Earnings Recovery In Vaccine Deaths
• Medicare Fraudster Can't Claim Double Jeopardy: 5th Circ.
• Valeant Will Pay Anacor $143M Over Anti-Fungal Dispute
• US Chamber, Others Push For Bill To Stop Counterfeit Imports
• Schulte Scores $21M Payday For Quigley Bankruptcy Work
• Catalyst's New Drug Was Old News, Investors Say
• Dow Pharmaceutical Asks Court To Block Generic Acne Gel
• Coming Soon: Paradigm Shift In Genetic Resources Regs
• Investors Rip Fee Request By Carella Byrne, Kessler Topaz
• Abbott Labs Wins FDA Approval For MitraClip Implant
• AstraZeneca Sues 4 Drugmakers To Stop Generic Vimovo
• FTC Pressed To Crack Down On Multilevel Marketers
• Hip Implant Recall Costs Could Top $1B, Stryker Says
• Novo Nordisk Recalls Insulin Pens All Over Europe
• DC Circ. Rejects Esai's Petition Over Seizure Med Delay
• Lumina Diet Supplement Class Action Stays In Fed. Court
• The Good, Bad And Ugly Of HIPAA-Compliant Texting
• US Chamber of Commerce Calls For False Claims Act Reform
• Ky. High Court Nixes Fen-Phen Malpractice Suit Against Firms
• FDA Pushes Tougher Controls On Hydrocodone Painkillers
• Nature's Products Hit With $3.3M Verdict Over Prolab Recall
• FDA Panel Chair Targeted Over Advice To Drug Cos.
• Senators Warn Of Possible Kickbacks Behind Back Surgeries
• AndroGel Judge Says It's Time To Revive Class Fight
• AstraZeneca Says Safe Harbor Dooms Crestor Patent Suit
• Digirad's Board Of Directors Election Valid, Judge Says
• The Inherent Risks In Purchasing Assets Of A Predecessor
• AARP Opposes 12-Year Exclusivity For Biologic Drugs In TPP
• USANA Flouted 'Live Person' Software License, Suit Says
• Stryker Settles FCPA Probe With $13M Payout
• GSK Can't Sink Avandia Prescription Coverage RICO Suits
• Effexor Pay-For-Delay Suit Awaits High Court's K-Dur Answer
• McKesson Inks $8.3B Deal To Scoop Up German Peer Celesio
• Troutman Sanders Nets Ex-McCarter Product Liability Atty
• FDA Urged To Get Specific In Facility Inspection Reports
• Generics Cos. Can't Pare Novartis Patent Infringement Suit
• Bipartisan Bill Would Curb FDA's Medical Apps Oversight
• Investor Can Lead SAC Class Action Despite Past Suits
• Olympus Surgical Says Rival Ignored Court Order In IP Case
• EFF Urges High Court To Strengthen Patent Claim Standards
• French Cos. Can't Shield Info From UK Antitrust Suits
• Former Bristol-Myers Exec Gets 1 Year For Insider Trading
• Fosun Pharma Unit Inks $533M Deal To Sell Medical IP Rights
• Cephalon Sues Eagle Over Plans For Liquid Treanda
• Defeating Economic Loss Claims In Pharma Class Actions
• Deals Rumor Mill: McKesson, Icahn, Safeway
• Omnicare Pays $120M To Settle Nursing Home Kickback Suit
• Judge Trims Doc's $2.2M Indemnity Suit Against Device Maker
• FDA's Stem Cell Oversight Faces Pivotal Test In DC Circ.
• Enzo's Contract Claims Over DNA Testing Tech Tossed
• EU Lawmakers Back Medical Device Reforms
• Genetics Testing Co. Seeks Out Ch. 11
• PE Firm Actis Sinks $48M Into India's Symbiotec Pharmalab
• NJ Court Tosses Columbia Labs Stock Drop Suit
• USPTO Explains AIA Review Deadline In Nixing St. Jude Case
• Takeda Sues Amneal Over Gout Drug Generic
• Baxter Says Generic Co. Infringed Hypertension Med Patent
• Bayer Hit With Trademark Suit Over Alka-Seltzer Brand
• Roche Diagnostics Denies Fired Manager's Age Bias Claims
• Gore Faces $1B In Patent Damages After Willfulness Finding
• Actelion Denied Judgment In Tracleer Antitrust Suit
• Arent Fox Nabs Ex-Dentons Patent Litigator
• New Walgreen Model Raises Privacy Concerns, Sen. Says
• Dodd-Frank Isn't For Foreign Whistleblowers, Judge Says
• FDA Cannot Regulate Stem Cell Treatments, DC Circ. Hears
• FDA Largely Rejects Prometheus Petition On Drug Risks
• EU-Canada Trade Pact Picks Up Industry, Gov't Backing
• High Court Won't Hear Novo Foreign Liability Case
• $2M Verdict Stands In Bard Vaginal Mesh Bellwether
• Anacor Scores $100M In Valeant Fungus Drug Feud
• How To Prepare Witnesses To Make (Not Break) Your Case
• A Lesson On Liability Risks For Device And Pharma Cos.
• Bulky Novartis Eyedrop Boxes Mislead Buyers, Calif. DAs Say
• Fed. Circ. Revives Bone Screw Patent Claim
• Fed. Circ. Won't Stop Transfer Of Eli Lilly Patent Suit
• Set The Right Tone For Risk Mitigation, Home And Abroad
• Keep An Eye On High Court's 2 Potential FCA Cases
• FDA Rebuffs Alimera Diabetes Eye Treatment Over Concerns
• McKesson Inks $37M Settlement In Drug Price-Rigging Suit
• Bard Pushes For Costs In Dropped Vaginal Mesh Bellwether
• GSK Dodges False Claims Kickback Suit Over HIV Drug
• Shutdown Threatens To Keep Product Safety Rules On Shelf
• Regulator Orders Becton, Rival To Tone Down Device Claims
• NYU Sues Pfizer Over Royalties For Cancer Drug Xalkori
• J&J Can't Stop Baby Sleep Aid False Ad Action
• Fed. Circ. Affirms Valeant Win In Antidepressant IP Battle
• FCA's Scope Widens As 8th Circ. Embraces Little-Used Theory
• PE-Backed Biotech Co. Egalet Prepares $69M IPO
• Pa. Justices Reject Wyeth's Appeal Of $11M Prempro Suit
• Boston Scientific To Pay $30M In Defibrillator FCA Suit
• Ariad Investor Says Drug Side Effects Led To Stock Drop
• Misbranded Drugs — A Danger To Physicians And Patients
• Deals Rumor Mill: BlackBerry, Men's Wearhouse, Nestle
• Bayer Escapes 60 Suits In Mass Tort Over Yaz, Yasmin
• Time Limit Dooms Nexium Antitrust Claims, AstraZeneca Says
• BioClinica Investors Lose Bid To Block $123M PE Takeover
• St. Jude Looks To Shoot Down Investors' Stock Fraud Suit
• Spotlight On State Urgent Care Regulation
• NAD Asks Supplement Maker To Ax Clinical Claims
• Zimmer, Marketer Push For Retrial In $28M Knee Injury Row
• Savient Gets Nod To Fund Ch. 11 Sale With Cash Collateral
• FDA Advises Against Antifungal Drug's Use In Studies
• Philips AirFloss Buyers Shafted In False Ad Deal, Group Says
• Braun Yanks Antibiotic Over Life-Threatening Particles
• 38 Drugmakers Tricked State Medicaid Agency, La. Says
• St. Jude Says Cancer Drug Research Infringes Patents
• AstraZeneca Unit Buys Biotech Co. Spirogen For $440M
• Supplements Contain Meth-Like Substance, Study Says
• Australian Regulators Target Caffeine Combo Stimulants
• FDA Lays Out Limits For Drug Impurities
• Herbalife Can't Dodge 'Pyramid Scheme' Class Action
• Supreme Court Won't Mull Hospira's Duty To Supply Drug
• Savient Pharmaceuticals Files For Ch. 11, Plans $55M Sale
• 8th Circ. Revives DOD Fraud Claims In Bayer FCA Suit
• Becton Seeks New Trial, Nix Of $114M Antitrust Verdict
• Robins Kaplan Lures FCA Pro From Justice Department
• Environ Lures Drinker Biddle Partner For GC Slot
• Calif. Governor Vetoes Biosimilars Substitution Bill
• Gov't Shutdown Impacts: Health Care Edition
• Clinton Group Pushes For CEO Ouster At Drugmaker XenoPort
• Dilworth Paxson Gave Negligent Advice, Cryogenics Co. Says
• Shareholders Hit Peregrine Pharma Over Exec Compensation
• Maine Law Muddles Liability In Drug Injury Suits
• Fed. Circ. Won't Review Ruling Nixing Cordis Stent Patents
• Coverage Row Over Teva Patent Deal Sent To Arbitration
• $9M Shaved From Novartis Jaw Injury Award By NY Judge
• Medtronic Surgery Advice Suit Not Preempted: Ind. Court
• The Best Question To Ask Your Potential Outside Counsel
• Deals Rumor Mill: KKR, Versace, Glencore
• Bard Berated For Fee Demand In Dropped Vaginal Mesh Suit
• Quest Says It's Not Infringing Myriad's Gene Patents
• FDA Eyes Ariad Leukemia Drug After Blood Clot Reports
• EU Panel Says Contraceptive Benefits Outweigh Clot Risks
• Making Refill Reminders: Not As Simple As You Think
• Merck KGaA Sues NJ Supplement Biz For Use Of Folate Mark
• Health Industry In Limbo As Shutdown Halts Rulemaking
• Shutdown Harms CDC's Outbreak Tracking, Dems Say
• Sen. Wants Probe Of Big Pharma Influence On Painkiller Regs
• Allergan Seeks Escape From Surgical Centers' Lap-Band Suit
• Challenges Under The French Sunshine Act
• Natrol Faces False Ad Suit Over Joint-Health Supplement
• Gibbons Snags Ex-Roche Chief Patent Counsel For IP Practice
• Van Bael & Bellis Draws Back Longtime Antitrust, IP Atty
• Jury Awards $29M To KFx In Suture Patent Row
• OIG Sounds Alarm On Medicare's $565M Sleep Study Bill
• Pharma Co. Misled Investors About Hepatitis Drug, Suit Says
• High Court Sets Stage For Momentous FCA Ruling
• FTC's Increasingly Aggressive Assertion Of Authority
• Device Maker Fights OIG's 'Inherently Suspect' Claim
• Maine Drug Importation Law Takes Effect Amid Controversy
• Ex-Eli Lilly Scientists Stole $55M In Secrets, Feds Say
• Pfizer Hit With Suit Claiming Lipitor Caused Diabetes
• Gov't Shutdown: A Setback For FDA's Momentum
• J&J Investors Defend Suit Over Ex-CEO's $175M Payout
• Calif. Gov. Signs Compounding Pharmacy Oversight Bill
• Gov't Shutdown Delays Merck's FDA Drug Hearing
• Butler Snow Lands Litigation Ace To Bolster Pharma Group
• Lessons From SIGA Technologies V. PharmAthene
• DePuy Says Ex-Sales Reps Breached Noncompetes
• FDA Links Deadly Hepatitis Cluster To Popular Supplement
• GNC Seeks Toss Of Muscle Supplement False Ad Row
• Quest Buys ConVerge Diagnostic Services From Water Street
• Bard Wants Atty Fees For Dropped Mesh Bellwether
• FDA Chides Device Maker Nidek Over Quality Controls
• Deals Rumor Mill: McKesson, Vodafone, Carlyle
• Stryker OK'd To File New Knee Coverage Claims Against TIG
• Jones Day Adds Ex-SDNY Civil Frauds Unit Chief
• Arent Fox Lures IP Guru From Dentons To SF Office
• EU Lawmakers Loosen E-Cig Regs In Anti-Tobacco Plan
• Let's Really Consider The Idea Of A 2-Year Law Degree
• Sun Pharma Can't Quell Patent Feud Over Epilepsy Drug
• Former Celgene Exec Settles SEC's Insider Trading Claims
• High Court Won't Block Puerto Rico's Control Of Drug Prices
• High Court Won't Mull Punitives In Drug Labeling Suits
• Stryker Unit Settles Trade Secrets Claims Against Zimmer
• Justices Won't Hear Design Defect Suit Over Generic Reglan
• J&J Escapes Damages In Suit Linking Body Powder To Cancer
• Pasteur Gene Targeting Patents Are Valid, Fed. Circ. Told
• Watchdog Shuts Down Supragenix, Wellnx Supplement Claims
• Judge Unveils Records In FOIA Suit Targeting Pfizer, Purdue
• High Court Wants SG's Views In Medtronic Pain Pump Row
• High Court Rejects Appeal To Reclassify Marijuana
• Pa. Superior Court Won't Rehear Reglan Preemption Appeal
• High Court Wants Government Input In Whistleblower Suits
• High Court Won't Review Feraheme Investor Class Action
• CSL To Pay $64M To Escape Blood Plasma Antitrust Suit
• Calif. Class Consumer Fraud Cases Continue To Survive
• Novartis' Sandoz Infringed On Pfizer Eye Drug Patents: Judge
• Liberty Medical Asks For SJ In $69M Whistleblower Claim
• High Court Asked To Review Nixed $600M Stent IP Verdict
• FDA Quality Grades Could Leave Drugmakers Smarting
• The Best Cyberdefense Is A Good Offense
• Adderall Antitrust Suit Should Stay Buried, 2nd Circ. Hears
• Judge Delays Wind-Down In MDL Over Merck's Fosamax
• Polsinelli's FDA Practice Leader Jumps To Fox Rothschild
• House Bill Would End Shutdown For FDA
• Deals Rumor Mill: BNP Paribas, Ikaria, Best Buy
• Dems Back Funding Bill Tied To Repeal Of ACA Device Tax
• Mass. House OKs Bill To Reform Compounding Regs
• VasoNova, CR Bard Settle Catheter Trade Secrets Case
• JPML Ships Loestrin Pay-For-Delay Suits To Rhode Island
• Holland & Knight Nabs Pharmaceutical Pro For IP Practice
• Neptune Tech. Settles ITC Action Over Krill Oil Patent
• J&J Settles Hip Implant Case Set For Trial In Calif.
• Celgene Accused Of Infringing Cancer Treatment Patent
• Considerations Before Counseling During Deposition
• Masimo Escapes FCA Row Over Allegedly Shoddy Devices
• Hospira Woes Continue As Glass Contamination Spurs Recall
• Dutch Court Sides With Teva In Spat Over MS Drug Patent
• Declaratory Judgment Act: Must Suppliers Bet The Farm?
• Arthrex Ordered To Stop Selling Infringing Suture Anchors
• Vitamin C Attys Get $10M For Work On Antitrust Settlements
• Omeros To Get $12.5M In Whistleblower Coverage Deal
• Ackman Pares Down $1B Herbalife Bet, Books Losses
• Biosimilars Guidance, Drugmaker Grades Coming, FDA Says
• Merck Opposes Delay In Wind-Down Of Fosamax MDL
• BioScrip Inc. Hit With Shareholder Suit Over Exjade Probe
• Fla.'s Recent Fight In The Zometa Evidentiary Battle
• Fed. Circ. Lifts Injunction On Hanmi's Generic Nexium
• Questcor Can't Kick Securities Fraud Case
• 3rd Circ. Ruling Imperils Consumer Class Actions, Group Says
• FDA Lays Out Rules For Early Study Of Higher-Risk Devices
• McDonald Hopkins Picks Up Ex-K&L Gates Health Care Pro
• Avista, Nordic Ink $439M Deal To Acquire Swiss Drugmaker
• Mako Bulks Up Surgical Biz Before $1.7B Stryker Takeover
• New Bill Would Perpetuate FDA-State Compounding Confusion
• Merck's $688M Vytorin Settlement Wins Judge's Nod
• Medical Co. Settles With US Over Iran Embargo Violations
• Wright Pushes FTC For More Pay-For-Delay Study
• FDA Withdrawing Approval For Some Toxic Animal Feed Drugs
• Pharma Trade Group Seeks To Stop HHS Orphan Drug Rule
• Shutdown Status Of Top 7 Gov't Antitrust Cases
• Rainmaker Q&A: Chamblee Ryan's Bill Chamblee
• Stryker Hit With Patent Suit Over Spinal Treatment Devices
• FDA Warns Of Potential Safety Issues In Nephron Asthma Drug
• Deals Rumor Mill: America Movil, Icahn, J&J
• Novartis Takes Aim At Cross-Appeal In Zometa Suit
• Don't Conflate Shutdown And Debt Ceiling Challenges
• FDA Details When It Won't Accept Generic Drug Applications
• Amgen, Actavis Close On Billion-Dollar Pharma Deals
• Pharmaceutical Patent Pro Joins Baker Botts In Houston
• Catheter Kickback FCA Suit Brings No New Proof, Bard Says
• Epstein Becker Green Adds Health Care Pro To Newark Office
• US Government Shuts Down As Funding Fight Goes Nowhere
• BigLaw Braces For Revenue Hit In Federal Shutdown
• User Fees Won't Save FDA Approvals From Shutdown's Snare